Xbrane Biopharma AB(DE:7XB0)
€0.88+0.00 (+0.23%)
DE:7XB0
Xbrane Biopharma AB financials statements
€0.88
At close:+0.00 (+0.23%)
Xbrane Biopharma AB (7XB0) Ratios
6 Followers
Xbrane Biopharma AB Ratios
DE:7XB0's free cash flow for Q3 2026 was kr4.08M. For the 2026 fiscal year, DE:7XB0's free cash flow was increased by kr999.00 and operating cash flow was kr4.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.12 | 1.13 | 1.41 | 2.17 | 2.55 |
| Quick Ratio | 3.43 | 0.67 | 1.09 | 1.96 | 1.57 |
| Cash Ratio | 1.64 | 0.23 | 0.20 | 0.82 | 1.34 |
| Solvency Ratio | 1.28 | -0.36 | -0.76 | -0.59 | -0.70 |
| Operating Cash Flow Ratio | -4.76 | -0.25 | -1.25 | -0.82 | -1.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -1.62 | -6.51 | 0.00 | 2.30 |
| Net Current Asset Value | kr 264.16M | kr -27.99M | kr -20.48M | kr 247.90M | kr 304.32M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.23 | 0.35 | 0.06 | 0.06 |
| Debt-to-Equity Ratio | 0.10 | 0.92 | 1.35 | 0.09 | 0.10 |
| Debt-to-Capital Ratio | 0.09 | 0.48 | 0.57 | 0.08 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.24 | 0.40 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.20 | 4.04 | 3.81 | 1.63 | 1.59 |
| Debt Service Coverage Ratio | -1.14 | -1.63 | -4.35 | -57.82 | 1.89 |
| Interest Coverage Ratio | -4.40 | -6.05 | -136.75 | -64.35 | -68.44 |
| Debt to Market Cap | 0.00 | 0.75 | 0.07 | 0.00 | -0.00 |
| Interest Debt Per Share | 0.05 | 23.15 | 115.39 | 22.61 | 28.24 |
| Net Debt to EBITDA | 1.71 | -0.37 | -0.59 | 1.04 | 1.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 52.23% | 90.83% | 14.82% | 71.23% | -5.93% |
| EBIT Margin | -20.41% | -109.67% | -127.14% | -287.97% | -1565.85% |
| EBITDA Margin | -10.83% | -91.58% | -118.14% | -259.20% | -1453.15% |
| Operating Profit Margin | -47.35% | -109.67% | -130.03% | -288.48% | -1564.18% |
| Pretax Profit Margin | -28.84% | -127.54% | -134.89% | -292.47% | -1588.71% |
| Net Profit Margin | 83.52% | -133.98% | -162.60% | -298.91% | -1656.22% |
| Continuous Operations Profit Margin | -30.30% | -133.38% | -134.89% | -292.47% | -1588.71% |
| Net Income Per EBT | -289.63% | 105.05% | 120.54% | 102.20% | 104.25% |
| EBT Per EBIT | 60.90% | 116.29% | 103.74% | 101.38% | 101.57% |
| Return on Assets (ROA) | 18.95% | -31.60% | -59.40% | -24.94% | -27.75% |
| Return on Equity (ROE) | 22.70% | -127.66% | -226.56% | -40.53% | -44.24% |
| Return on Capital Employed (ROCE) | -11.66% | -71.57% | -94.95% | -36.62% | -38.48% |
| Return on Invested Capital (ROIC) | -11.66% | -54.45% | -77.06% | -35.89% | -47.31% |
| Return on Tangible Assets | 33.92% | -39.46% | -70.09% | -29.26% | -29.90% |
| Earnings Yield | 0.82% | -134.61% | -15.33% | -0.93% | -0.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.39 | 0.85 | 3.35 | 1.21 | 0.23 |
| Payables Turnover | 8.13 | 0.08 | 6.56 | 0.71 | 0.30 |
| Inventory Turnover | 0.37 | 0.07 | 1.90 | 0.33 | 0.06 |
| Fixed Asset Turnover | 4232.06 | 3.06 | 2.71 | 0.81 | 0.16 |
| Asset Turnover | 0.23 | 0.24 | 0.37 | 0.08 | 0.02 |
| Working Capital Turnover Ratio | 0.78 | 1.96 | 1.16 | 0.19 | 0.04 |
| Cash Conversion Cycle | 958.75 | 514.17 | 245.04 | 894.35 | 6794.29 |
| Days of Sales Outstanding | 29.47 | 427.42 | 108.83 | 300.63 | 1590.42 |
| Days of Inventory Outstanding | 974.20 | 4944.81 | 191.81 | 1106.71 | 6440.55 |
| Days of Payables Outstanding | 44.91 | 4858.05 | 55.60 | 512.99 | 1236.67 |
| Operating Cycle | 1003.66 | 5372.23 | 300.63 | 1407.34 | 8030.97 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.16 | -13.59 | -200.76 | -107.47 | -131.90 |
| Free Cash Flow Per Share | -0.26 | -18.90 | -209.04 | -140.79 | -178.36 |
| Dividend Paid and CapEx Coverage Ratio | -1.80 | -2.56 | -24.25 | -3.23 | -2.84 |
| Capital Expenditure Coverage Ratio | -1.80 | -2.56 | -24.25 | -3.23 | -2.84 |
| Operating Cash Flow Coverage Ratio | -4.30 | -0.70 | -1.76 | -5.07 | -4.95 |
| Operating Cash Flow to Sales Ratio | -1.65 | -0.67 | -1.70 | -3.37 | -19.04 |
| Free Cash Flow Yield | -2.51% | -94.04% | -16.72% | -1.37% | -1.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 122.01 | -0.73 | -6.52 | -107.52 | -114.18 |
| Price-to-Sales (P/S) Ratio | 101.88 | 1.00 | 10.61 | 321.39 | 1891.13 |
| Price-to-Book (P/B) Ratio | 27.69 | 0.95 | 14.78 | 43.58 | 50.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -39.77 | -1.06 | -5.98 | -72.89 | -73.45 |
| Price-to-Operating Cash Flow Ratio | -61.92 | -1.48 | -6.23 | -95.49 | -99.31 |
| Price-to-Earnings Growth (PEG) Ratio | -1.22 | 0.01 | -0.10 | 7.44 | 3.16 |
| Enterprise Value Multiple | -939.14 | -1.46 | -9.57 | -122.95 | -128.64 |
| Enterprise Value | 15.49B | 265.16M | 2.70B | 18.36B | 21.56B |
| EV to EBITDA | -939.14 | -1.46 | -9.57 | -122.95 | -128.64 |
| EV to Sales | 101.70 | 1.33 | 11.30 | 318.68 | 1869.39 |
| EV to Free Cash Flow | -39.69 | -1.43 | -6.37 | -72.28 | -72.60 |
| EV to Operating Cash Flow | -61.81 | -1.98 | -6.63 | -94.69 | -98.17 |
| Tangible Book Value Per Share | 0.17 | 4.15 | 35.38 | 178.95 | 229.48 |
| Shareholders’ Equity Per Share | 0.37 | 21.19 | 84.58 | 235.47 | 259.32 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.05 | -0.05 | 0.00 | 0.00 | -0.04 |
| Revenue Per Share | 0.10 | 20.19 | 117.85 | 31.93 | 6.93 |
| Net Income Per Share | 0.08 | -27.06 | -191.63 | -95.45 | -114.73 |
| Tax Burden | -2.90 | 1.05 | 1.21 | 1.02 | 1.04 |
| Interest Burden | 1.41 | 1.16 | 1.06 | 1.02 | 1.01 |
| Research & Development to Revenue | 0.77 | 1.57 | 1.28 | 3.47 | 13.93 |
| SG&A to Revenue | 0.29 | 0.20 | 0.17 | 0.55 | 2.72 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.15 | 0.39 |
| Income Quality | 5.43 | 0.50 | 1.05 | 1.12 | 1.17 |
Currency in SEK

